Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(17%)

Phase Distribution

Ph phase_2

67%

Ph phase_3

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

4(80.0%)

Phase 3Large-scale testing

1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(2)

Other(1)

Detailed Status

Completed3

Withdrawn1

Terminated1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 3

Trials by Phase

Phase 24 (80.0%)

Phase 31 (20.0%)

Trials by Status

completed350%

withdrawn117%

terminated117%

unknown117%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_3

Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant

NCT00790439

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT00434811Phase 3

Islet Transplantation in Type 1 Diabetes

Completed

NCT00468403Phase 2

LEA29Y (Belatacept) Emory Edmonton Protocol

Completed

NCT00468442Phase 2

B-Lymphocyte Immunotherapy in Islet Transplantation

Terminated

NCT00434850Phase 2

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

Completed

NCT00790439Phase 2

Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant

Withdrawn

NCT01049633

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

Unknown

All 6 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 6